Edwards Lifesciences (EW) Equity Average (2016 - 2025)
Edwards Lifesciences (EW) has 16 years of Equity Average data on record, last reported at $10.3 billion in Q4 2025.
- For Q4 2025, Equity Average rose 4.41% year-over-year to $10.3 billion; the TTM value through Dec 2025 reached $10.3 billion, up 4.41%, while the annual FY2025 figure was $10.2 billion, 21.56% up from the prior year.
- Equity Average reached $10.3 billion in Q4 2025 per EW's latest filing, down from $10.4 billion in the prior quarter.
- Across five years, Equity Average topped out at $10.4 billion in Q3 2025 and bottomed at $4.6 billion in Q1 2021.
- Average Equity Average over 5 years is $7.2 billion, with a median of $6.4 billion recorded in 2023.
- Peak YoY movement for Equity Average: rose 1.61% in 2023, then surged 46.32% in 2024.
- A 5-year view of Equity Average shows it stood at $5.7 billion in 2021, then grew by 5.69% to $6.0 billion in 2022, then grew by 11.83% to $6.7 billion in 2023, then soared by 46.32% to $9.8 billion in 2024, then increased by 4.41% to $10.3 billion in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $10.3 billion in Q4 2025, $10.4 billion in Q3 2025, and $10.4 billion in Q2 2025.